• Pfizer, Valneva Lyme vaccine candidate PF-07307405 marketing application validated by the EMA, triggering the start of the agency’s review.
• Filing backed by Phase 3 VALOR data showing more than 70% efficacy in people aged 5 and older; no safety concerns identified.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260813472879) on August 14, 2026, and is solely responsible for the information contained therein.